News of Note—TapImmune’s breast cancer combo, IAVI’s HIV vaccine and more

In this week's news of note, the DOD grants $11 million for a TapImmune breast cancer study. (PIxabay)

Here is some other vaccine news of note for the week.

> With a grant of $11 million from the U.S. Department of Defense, investigators will test TapImmune’s breast cancer vaccine, TPIV110, in combination with Roche's Herceptin in a phase 2 study. Release

> The International AIDS Vaccine Initiative has started human testing of a novel HIV vaccine designed to initiate a key first step in the generation of broadly neutralizing antibodies. Release

> The University of Montana won a $10 million, five-year contract from the NIH to develop a new universal flu vaccine. Release

> Valneva nabbed FDA approval for an accelerated, seven-day dosing regimen for Japanese encephalitis vaccine Ixiaro. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.